The severity levels of hemophilia are determined by the level of residual/remaining clotting factor (factor VIII or factor IX) activity in the patient’s blood, which is denoted by the percentage of factor activity in the blood (or international units per ml of blood – IU/ml). According to the World Federation of Hemophilia,…
Search results for:
Some hemophilia patients may, over time, develop inhibitors which restrict the efficacy of treatment making bleeding episodes more difficult to stop. MORE: Intracranial hemorrhage risk – when to see a doctor According to the Centers for Disease Control and Prevention (CDC), although the majority of people living with…
Understanding hemophilia treatment options if you have inhibitors
Fact-Checked By Lindsey Shapiro, PhD
Hemophilia inhibitors can reduce treatment effectiveness and raise bleeding risks, but several therapies can help maintain control. Understanding your options can support more confident, informed care decisions.
Hemophilia can affect everyone differently, depending on your symptoms, the type of hemophilia you have, and its severity. This is why your care team should be based on your individual needs. But regardless of the specific specialists, you want a coordinated, comprehensive, multidisciplinary team of healthcare professionals…
People with hemophilia may benefit from mild exercise to minimize their risk of bleeding according to a study published in the scientific journal Haemophilia.
Labor and delivery in women with hemophilia Planning for childbirth depends on the needs of the mother and the child affected by hemophilia. Levels of clotting factors should be measured in the last trimester of pregnancy, since it is difficult to measure during labor. If levels are low, treatment may…
Approximately 30,000 males have hemophilia in the U.S., according to estimates from a recent study, which also found that patients with hemophilia are generally young and that the disease is more common in Northeastern and Midwestern states. The study, “Occurrence rates of haemophilia among males in…
An enzyme called activate protein C (APC), which prevents the formation of blood clots and therefore promotes bleeding could be targeted to treat hemophilia, suggests a study conducted by researcher at the University of Cambridge and the Children’s Hospital of Philadelphia.